Stryker Co. (NYSE:SYK) Shares Bought by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Stryker Co. (NYSE:SYK) by 7.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,477 shares of the medical technology company’s stock after buying an additional 561 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Stryker were worth $2,539,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SYK. Vanguard Group Inc. grew its position in shares of Stryker by 0.5% in the third quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after purchasing an additional 143,631 shares in the last quarter. FMR LLC lifted its stake in Stryker by 2.5% during the third quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock worth $1,632,127,000 after purchasing an additional 144,208 shares in the last quarter. Morgan Stanley lifted its stake in Stryker by 4.4% during the third quarter. Morgan Stanley now owns 5,315,227 shares of the medical technology company’s stock worth $1,452,493,000 after purchasing an additional 223,728 shares in the last quarter. Northern Trust Corp lifted its stake in Stryker by 3.9% during the third quarter. Northern Trust Corp now owns 3,505,595 shares of the medical technology company’s stock worth $957,974,000 after purchasing an additional 131,590 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Stryker by 2.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,740,456 shares of the medical technology company’s stock worth $475,614,000 after purchasing an additional 40,736 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the company. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. TD Cowen increased their price objective on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Evercore ISI increased their price objective on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and increased their price objective for the company from $315.00 to $360.00 in a research note on Wednesday, January 31st. Finally, Citigroup increased their price objective on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $340.67.

Stryker Price Performance

Shares of Stryker stock traded up $0.09 during trading on Thursday, hitting $336.94. 509,687 shares of the company were exchanged, compared to its average volume of 1,272,504. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The stock has a market capitalization of $128.20 billion, a price-to-earnings ratio of 40.83, a P/E/G ratio of 2.70 and a beta of 0.89. The firm has a 50 day moving average price of $349.39 and a 200 day moving average price of $314.24.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the firm posted $3.00 EPS. The company’s quarterly revenue was up 11.8% compared to the same quarter last year. On average, equities analysts expect that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 annualized dividend and a yield of 0.95%. Stryker’s payout ratio is currently 38.79%.

Insiders Place Their Bets

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. In the last three months, insiders sold 212,109 shares of company stock valued at $72,845,768. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.